



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Gary R. Braslawsky et al)
) Group Art Unit: 1642
Application No. 09/238,741)
) Examiner: L. Helms
Filed: January 28, 1999)
)
For: PRODUCTION OF TETRAVALENT)
ANTIBODIES)

REPLY PURSUANT TO 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action [Non-Final Rejection] dated October 25, 2000, please amend the above-identified application as follows.

In the Specification:

Page 22, please delete the paragraph beginning at line 8 and replace it with the following paragraph:

Through the use of conventional in vitro site directed mutagenesis, applicants effected a transversion mutation C to G within the plasmid DNA (Figure 3). This IDEC proprietary expression construct (Reff et al., U.S. Patent Appl. Serial No. 08/819,866, filed March 14, 1997, now U.S. Patent No. 5,830,698) encodes the anti-CD20 immunoglobulin light and heavy chains, as well as sequences necessary for homologous integration into a proprietary CHO cell line Reff et al. IBID), followed by dominant selection with G418 and/or methotrexate. The affect of this nucleotide mutation is to change the

terminus (see Figure 2).